106 articles on gene editing and biotech
A comprehensive investor's guide to gene editing — from genomics ETFs (ARKG, GNOM, IDNA) and longevity venture funds to publicly traded companies across 12 countries and the indexes tracking this sector.
Prime editing can rewrite DNA with surgical precision — no double-strand breaks, no bystander mutations, no RNA off-targets. From PE1 to PE7, from the lab to the NEJM, here is the definitive guide to the most versatile gene editing tool ever created.
Epigenetic reprogramming uses Yamanaka factors to wind back the biological clock of aged cells, offering one of the most promising paths to reversing aging itself.
Life Biosciences launched the first-ever human trial of epigenetic reprogramming in January 2026 — an AAV gene therapy that uses three Yamanaka factors to reverse aging in the eye. Here's the full story of the company, its science, and what it means for the future of longevity medicine.
New to gene editing? This beginner-friendly guide explains what CRISPR is, how it works, and why it has become the most important biotechnology tool of the 21st century.
The 12 hallmarks of aging provide a scientific framework for understanding why we age and where interventions might slow or reverse the process.
Senolytic drugs and gene therapies that selectively destroy aged 'zombie' cells are emerging as one of the most promising strategies to combat age-related disease.
From billion-dollar reprogramming ventures to canine longevity drugs, here are the biotech companies leading the charge against aging in 2026.
Telomeres — the protective caps on your chromosomes — shorten with every cell division, acting as a biological countdown clock that shapes aging, cancer, and the limits of cellular life.
Gene therapy is moving beyond treating rare diseases to targeting aging itself, with AAV-delivered rejuvenation genes showing dramatic results in animal models and the first human experiments already underway.
A look at the publicly traded gene editing companies best positioned for 2026, from the first approved CRISPR therapy to next-generation platforms targeting cardiovascular disease and cancer.
A comprehensive introduction to CRISPR-Cas9 gene editing, covering its discovery, molecular mechanism, real-world applications, and the ethical questions it raises.